HC Wainwright Has Pessimistic Outlook of FHTX Q3 Earnings

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Investment analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.84) EPS, FY2029 earnings at ($0.84) EPS and FY2030 earnings at ($0.72) EPS.

Several other brokerages also recently commented on FHTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Foghorn Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.43.

Foghorn Therapeutics Stock Up 2.8%

NASDAQ:FHTX opened at $6.24 on Tuesday. Foghorn Therapeutics has a twelve month low of $3.27 and a twelve month high of $6.95. The stock’s 50-day simple moving average is $4.77 and its 200 day simple moving average is $4.96. The firm has a market capitalization of $370.53 million, a PE ratio of -6.37 and a beta of 2.89.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.14. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $6.80 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FHTX. Brummer Multi Strategy AB bought a new position in Foghorn Therapeutics during the 4th quarter worth $25,000. Russell Investments Group Ltd. boosted its holdings in shares of Foghorn Therapeutics by 13,755.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock worth $27,000 after buying an additional 5,502 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock worth $35,000 after purchasing an additional 2,305 shares during the period. Tower Research Capital LLC TRC increased its position in Foghorn Therapeutics by 136.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock valued at $43,000 after buying an additional 5,323 shares in the last quarter. Finally, Strs Ohio raised its stake in Foghorn Therapeutics by 120.5% during the 4th quarter. Strs Ohio now owns 8,600 shares of the company’s stock worth $46,000 after buying an additional 4,700 shares during the period. Institutional investors and hedge funds own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.